Sign Up For Our
FREE Newsletter


Timely Market Commentary
Daily Stock Picks
News Analysis

Email Address: * Required

Country:
Zipcode:

 
 

Archive

Author Archive

EQLB, TNDM, ARJ, CRWEWallstreet.com Stock to Highlight! September 9th 2010

September 9th, 2010 The Editor

signup3m

The convenience of convenience!

Terrible Herbst now a distribution center for EQ energy drink’s, convenience stores are located in Chevron gas stations with point of purchase advertising displays. As a result of the closing of this deal with Terrible Herbst, EQ Labs will also receive point of purchase advertising at over 100 stores.

Mo Owens, Chief Executive Officer of EQ Labs, stated, “This order is confirmation of the popularity of EQ. We have spent a lot of time and energy building our brand. This order provides the economic benefit of a large order. In addition, the advertising opportunity and the desired location of many of Terrible Herbst’s locations will place our product line in front of millions of potential customers. “

This visibility is worth how much?

About Today Press release:

EQ Labs Inks Agreement for Large Purchase Order to Place EQ Energy Drink in Major Convenience Store Chain!

EQ Labs, Inc. (EQLB.PK) closed a deal with Terrible Herbst Corporation to place EQ Energy Drink in 108 Terrible Herbst convenience stores effective immediately, today. EQ Labs expects to receive a large commercial order for its energy drink to stock all 108 Terrible Herbst stores within the next 30 days.

Terrible Herbst Corporation owns and operates gas stations and convenience stores in Nevada, California, Utah and Arizona. It also engages in operating car wash facilities, casinos, hotels, parks, slot routes, and motor sports, as well as in car lube and detail operations. The company was founded in 1937 and is based in Las Vegas, Nevada.

Many of the Terrible Herbst convenience stores are located in Chevron gas stations with point of purchase advertising displays. As a result of the closing of this deal with Terrible Herbst, EQ Labs will also receive point of purchase advertising at over 100 stores.

Mo Owens, Chief Executive Officer of EQ Labs, stated, “This order is confirmation of the popularity of EQ. We have spent a lot of time and energy building our brand. This order provides the economic benefit of a large order. In addition, the advertising opportunity and the desired location of many of Terrible Herbst’s locations will place our product line in front of millions of potential customers. This deal would not be possible without the help of Mark Walters and Rio Valentino. Mark Walters, Director of Merchandising and Sales for Terrible Herbst is an expert in the sales and merchandising business. We are also consummating a relationship with a major distributor as a result of Mark’s extensive relationships. I also can’t forget Rio Valentino, our Vice President of Sales. Rio’s persistence and skills is one of the biggest reasons why are sales are beginning to accelerate and we hope to make many more announcements like this one over the near future. This is a very big moment for our company.

More about EQLB at: www.drinkeq.com

Keep your eyes on EQLB and be ready for possible pop!

http://crwewallstreet.com/img/tndm_logo.jpg

Neutral Tandem, Inc. (Nasdaq:TNDM), a leading provider of interconnection services, announced today it has entered into an agreement to acquire Tinet SpA, an Italian based global carrier exclusively committed to the IP Transit and Ethernet wholesale market. To acquire Tinet, Neutral Tandem will pay cash consideration of approximately 74.5 million euros (approximately $94.9 million), which reflects certain purchase price adjustments, the assumption of approximately 5.2 million euros in cash (approximately $6.6 million) and the assumption of approximately 18.2 million euros in long-term debt (approximately $23.2 million), which will be paid off at closing1. The combination will immediately expand Neutral Tandem’s IP-based network internationally, enabling global end-to-end delivery of wholesale Voice, IP and Ethernet solutions. The acquisition, to be financed by cash from Neutral Tandem’s balance sheet, is subject to various standard closing conditions and is expected to close during the fourth quarter of 2010. After closing, Tinet will be a wholly owned subsidiary of Neutral Tandem.

“This acquisition redefines Neutral Tandem from a strictly voice interconnection company into a global IP-based network services company focused on delivering global connectivity for a variety of media, including voice, data and video,” said Rian Wren, President and CEO of Neutral Tandem. “Furthermore, the integration of Tinet’s global IP backbone will help accelerate and expand Neutral Tandem’s and Tinet’s Ethernet services. This combination will take our Ethernet eXchange service global and will position us for delivering cost-effective wholesale Ethernet interconnectivity solutions end-to-end.”

More about TNDM at: www.neutraltandem.com

http://crwewallstreet.com/img/arj_logo.jpg

Arch Chemicals, Inc. (NYSE:ARJ) announced that it entered into an agreement with certain institutional investors providing for a private placement of $250 million aggregate principal amount of 4.0% unsecured senior notes due December 31, 2017. The Company issued $125 million principal amount of the notes at closing and the remaining $125 million of notes will be issued on or before December 31, 2010 subject to customary closing conditions. Proceeds from the issuance of the notes will be used for general corporate purposes, including the repayment of the $80 million outstanding on its term loan facility.

Arch Chemicals’ Senior Vice President and CFO Steven C. Giuliano said: “We’re extremely pleased to have completed this new financing agreement. It provides us with a long-term source of funding at a historically-attractive interest rate and provides additional liquidity well in advance of the maturity of our primary bank credit facilities in June 2011. This private placement of seven-year 4.0% notes further strengthens our balance sheet, provides us with additional financial flexibility and enhances our capability to support the long-term, profitable growth prospects in our core Biocides businesses.”

More about ARJ at: www.archchemicals.com

Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

******************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (EEA, Inc ) for (7) days of advertising for EQ Labs, Inc. (EQLB.PK).

http://crwewallstreet.com/img/crwewallstreet_buscard.jpg

 
Share/Bookmark
 
 
 

EQLB, GLRE, RAVN, CRWEWallstreet.com Stock Report! September 9th 2010

September 9th, 2010 The Editor

signup3m

EQ Labs, Inc. (Pink Sheets:EQLB) closed a deal with Terrible Herbst Corporation to place EQ Energy Drink in 108 Terrible Herbst convenience stores effective immediately. EQ Labs expects to receive a large commercial order for its energy drink to stock all 108 Terrible Herbst stores within the next 30 days.

EQ Labs will also receive point of purchase advertising at over 100 stores in Nevada, California, Utah and Arizona.

EQLB is engaged in the development, marketing and sale of EQ (”The Smart Energy Drink”). EQ is an effervescent tablet that can be dissolved in any beverage to provide instant energy, consisting of a blend of essential vitamins, Gingko Biloba, and less caffeine than a cup of coffee. EQ is currently sold at Best Buy, 7-Eleven, Walgreens and other leading retailers.

EQ’s formula was invented to consist of FDA-approved ingredients that are not as harsh or overbearing as some of the energy drink products on the market. As a result, it has been dubbed the “Smart Energy Drink.

EQ is already in demand on the U.S. West Coast, but equal appeal and demand exists on the U.S. East Coast, in places like Miami, Tampa, and Atlanta. The product enjoys a presence in several thousand national retail outlets.

EQLB launched a nationwide promotion at the Las Vegas Boulevard location of Walgreens on Labor Day weekend. This Company is energized for the future and we will be watching.

More about EQLB at: www.drinkeq.com

http://crwewallstreet.com/img/ravn_logo.jpg

Raven Industries, Inc. (Nasdaq:RAVN) and Jacto Inc. are excited to announce a strategic partnership in which Raven will be Jacto’s precision ag partner for factory-installed components and the precision ag supplier for their global dealer network.

“Jacto and Raven’s partnership brings together two of the strongest companies in the application business, and provides a competitive product offering to customers all over the world,” said Matt Burkhart, Vice President and General Manager for Raven Industries, Applied Technology Division. “They share in our vision of providing comprehensive, simple to use solutions for operators and growers.”

Branded as “Otmis,” Jacto will be offering Raven precision products including GPS guidance, assisted steering, and automatic section control, with a focus on products that offer customers an attractive return on their investment.

“We are very excited about this partnership. Raven technology reinforces our position in Precision Agriculture, and Jacto has a tradition in building long term relationships. This is a key factor for the creation of innovative solutions for our customers,” said Pedro Estevao Bastos de Oliveira, Jacto New Business Development Director.

These products are now available through the Jacto dealer network.

More about RAVN at: www.ravenind.com

http://crwewallstreet.com/img/glre_logo.jpg

Greenlight Capital Re, Ltd. (Nasdaq:GLRE) today announced the formation of a new subsidiary, Greenlight Reinsurance Ireland, Ltd., to expand the company’s international presence and provide a platform to serve clients in the European market.

David Maguire, an experienced reinsurance and insurance executive with 19 years in positions of increasing executive responsibility in underwriting, rating and risk management, was named General Manager of Greenlight Re Ireland. Mr. Maguire has previously held management and underwriting positions at Travelers, Hannover Re, QBE and Lloyd’s of London. The company will be headquartered in the International Financial Services Centre in Dublin.

“We are excited to expand our presence and to leverage our expertise with our clients and partners in the European Union,” said Len Goldberg, CEO of Greenlight Re. “We particularly look forward to partnering with our clients and their brokers to help them fully appreciate the impact of Solvency II on their businesses, and to explore unique opportunities to enhance their capital position through the utilization of reinsurance.”

More about GLRE at: www.greenlightre.ky

 

 

Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

 

 

******************************************************************************

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (EEA, Inc ) for (7) days of advertising for EQ Labs, Inc. (EQLB.PK).

http://crwewallstreet.com/img/crwewallstreet_buscard.jpg

 
Share/Bookmark
 
 
 

ORFG, CBIS, PWER, CRWEWallstreet.com Stock Report! September 9th 2010

September 9th, 2010 The Editor

signup3m

Results from mineralized and un-mineralized material samples, as well as selected representative samples collected from its Colombian projects ran higher than expected in gold, silver and copper, has given the precious metals acquisition, exploration, and development company Orofino four very strong targets and two extremely rich structures to target for gold and copper.

Orofino Gold Corp., (ORFG.PK) will now implement an airborne magnetometer program, as well as begin site preparation for the diamond drilling planned to take place in the second quarter of 2010.

Gold has a lot of uses besides as a currency, or medium of exchange, Gold is used for rings, watches, and necklaces, its main use is mostly jewelry, but gold leaf is used in some foods, gold also is used in a lot of high end electronics because it is a good conductor.

Gold is useful in making ornaments, decorative linings and in electrical contacts for better conductivity. Gold could also be used with TV’s, phones, and many other items.

More about ORFG at: www.orofinogold.com

http://crwewallstreet.com/img/cbis_logo.jpg

Cannabis Science, Inc. (OTCBB:CBIS.OB), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.

 

On August 30, 2010, FOX affiliate KTXL (”FOX40″) aired one of the first paid U.S. television ads for a Cannabis Dispensary called CannaCare on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. Similarly, Cannabis Science is acquiring public testimonials using data acquired from RockBrook patients who use Cannabis Science Brands to evaluate our medical marijuana products prior to FDA clinical trials. Here

 

“It is a matter of record within the medical community that medical marijuana can have positive results in helping relieve nausea and vomiting among cancer patients receiving chemotherapy and increasing appetites among AIDS patients,” Mike Armstrong, acting general manager of KTXL in Sacramento, said in a statement e-mailed to FOX40.com, alluding that the ad is no different from that of any medicine advertised by pharmaceutical companies on local television channels and cable networks for decades. Here

 

Cannabis Science President and CEO Dr. Robert Melamede, PhD., noted, “The FOX40 ad sets a new milestone for general public acceptance of medical cannabis. Centuries of knowledge record that cannabis is an efficacious medicinal treatment for a host of ailments, yet governments continues to cling to clouded ideologies against this natural medicine and instead support man-made pharmaceuticals that often produce more harm than medicinal good. We are optimistic that the unique holistic value of medical cannabis, with its ability to supplement our natural endocannabinoid system will continue to spread throughout the country and the world. Dispensaries currently lead the way throughout California and other U.S. states, such as Colorado where our licensed dispensary is located. The Company sees this as an opportune time to expand the marketing of its products and licensing dispensaries. We look forward to future TV marketing campaigns for Cannabis Science products and our licensed RockBrook dispensary.”

 

Richard Cowan, Cannabis Science CFO, added, “We are encouraged that mainstream media is accepting medical cannabis dispensary advertisements in California, which is opening the door for us to expand the advertisement of our own licensed dispensary and products. On August 30, 2010, FOX affiliate KTXL (”FOX40″) aired the first ever-paid U.S. television ad for a medical cannabis dispensary on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. From a marketing perspective, this is a huge leap forward in giving medical cannabis dispensaries the opportunities that chemically manufactured medicines have long held.”

 

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

More about CBIS at: www.cannabisscience.com

http://crwewallstreet.com/img/pwer_logo.jpg

Power-One, Inc. (Nasdaq:PWER), a leading provider of renewable energy and energy-efficient power conversion and power management solutions, announced today that it will open its new manufacturing facility in Phoenix, Arizona. The Power-One Phoenix facility will produce its industry-leading photovoltaic and wind inverters, including single phase (2-6KW) and three phase string inverters, and NEMA 3R 250KW, 300KW and 400KW central inverters. In the future, for wind applications, the product range will include 2.5 MW inverters.

Production will commence in October 2010 and the facility is anticipated to support more than 350 new jobs in Arizona and throughout the United States. The new manufacturing plant will reach an annual inverter production capacity of 1.0 GW by mid 2011.

“Power-One is pleased to announce the opening of its new renewable energy manufacturing facility in Phoenix,” said Richard Thompson, President and Chief Executive Officer of Power-One. “We are excited to bring our field-proven products to the United States and Canadian markets, as we see tremendous growth opportunities in North America.”

More about PWER at: www.Power-One.com

Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

******************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 500,000 shares of 144 stock in Orofino Gold Corp. (OTC:ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising services.

http://crwewallstreet.com/img/crwewallstreet_buscard.jpg

 
Share/Bookmark
 
 
 

RockBrook Gears Up to Commercialize the Cannabis Science Brand of Pharmaceutical Products as It Airs One of the First Paid TV Ads on FOX Affiliate KTXL

September 9th, 2010 The Editor

COLORADO SPRINGS, Colo., Sept. 9, 2010 (CRWENEWSWIRE) — Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.

On August 30, 2010, FOX affiliate KTXL (”FOX40″) aired one of the first paid U.S. television ads for a Cannabis Dispensary called CannaCare on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. Similarly, Cannabis Science is acquiring public testimonials using data acquired from RockBrook patients who use Cannabis Science Brands to evaluate our medical marijuana products prior to FDA clinical trials.

See: http://abcnews.go.com/Business/medical-marijuana-commercial-airs-california/story?id=11547326

“It is a matter of record within the medical community that medical marijuana can have positive results in helping relieve nausea and vomiting among cancer patients receiving chemotherapy and increasing appetites among AIDS patients,” Mike Armstrong, acting general manager of KTXL in Sacramento, said in a statement e-mailed to FOX40.com, alluding that the ad is no different from that of any medicine advertised by pharmaceutical companies on local television channels and cable networks for decades.

See: http://www.fox40.com/news/headlines/ktxl-news-potad0830,0,5605124.story

Cannabis Science President and CEO Dr. Robert Melamede, PhD., noted, “The FOX40 ad sets a new milestone for general public acceptance of medical cannabis. Centuries of knowledge record that cannabis is an efficacious medicinal treatment for a host of ailments, yet governments continues to cling to clouded ideologies against this natural medicine and instead support man-made pharmaceuticals that often produce more harm than medicinal good. We are optimistic that the unique holistic value of medical cannabis, with its ability to supplement our natural endocannabinoid system will continue to spread throughout the country and the world. Dispensaries currently lead the way throughout California and other U.S. states, such as Colorado where our licensed dispensary is located. The Company sees this as an opportune time to expand the marketing of its products and licensing dispensaries. We look forward to future TV marketing campaigns for Cannabis Science products and our licensed RockBrook dispensary.”

Richard Cowan, Cannabis Science CFO, added, “We are encouraged that mainstream media is accepting medical cannabis dispensary advertisements in California, which is opening the door for us to expand the advertisement of our own licensed dispensary and products. On August 30, 2010, FOX affiliate KTXL (”FOX40″) aired the first ever-paid U.S. television ad for a medical cannabis dispensary on its FOX40 Live morning news program. The 30-second ad focused on cannabis relief (treatment) for various medical ailments using true-life patient testimonials. From a marketing perspective, this is a huge leap forward in giving medical cannabis dispensaries the opportunities that chemically manufactured medicines have long held.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:

Cannabis Science, Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Investor Relations
Mark J. Friedman
1-877-431-CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com

 

********************************************************************

CRWEnewswire is not liable for the contents of this news, as well as not being liable for any errors or delays in the content, or for any actions taken in reliance thereon.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB)

 
Share/Bookmark
 
 
 

NOC, CBIS, WPNV, CRWEWallstreet.com Stock Report! September 9th 2010

September 9th, 2010 The Editor

signup3m

http://crwewallstreet.com/img/cbis_logo.jpg

Cannabis Science Inc (OTCBB:CBIS.OB) is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

CBIS has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.

CBIS is vigorously seeking entry into the European medical cannabis market on the footsteps of GW Pharmaceuticals plc (GWPharm.com), a UK based commercial cannabinoid pharmaceutical company, which paved the way with the introduction and approval of its product, Sativex(R) in the UK and now Spain, which gave its regulatory approval on July 28, 2010. Currently Sativex(R) is approved in the UK and Spain as a prescription medicine for treatment of MS spasticity and in Canada for relief of neuropathic pain and advanced cancer pain.

In total, the medicine has been exported to 28 countries for either named patient prescription use or for clinical trial purposes. FDA clinical trials are currently in progress in the U.S. for administering Sativex(R) as an adjunctive analgesic treatment for cancer. GW has raised working capital of over $90 million through the public markets. In addition, GW has received signature licensing and milestone payments for prescription cannabinoid medicines and clinical trials totaling over $60 million to date, with over $365 million in future milestone payments slates plus effective royalties of 20-30%. In June 2010, GW received a valuation of over $300 million ([Pounds]158m) 1 based on its single Sativex(R) product.

More about CBIS at: www.cannabisscience.com

http://crwewallstreet.com/img/wpnv_logo.jpg

WINDPOWER INNOVATIONS, INC. (PINK SHEETS: WPNV), a wind power infrastructure and smart grid solutions company, announced today the availability of a recent interview with Chief Technical Officer Ian K. Griffiths conducted by Virmmac.com, a virtual IR, marketing, media, and administration center focused on providing companies ongoing support, and Stocktalk101.com, designed to educate traders and investors alike in OTC and Pink sheet companies, will air the interview via a pod cast, on Tuesday, September 7th, 2010 at 09:00 am EDT.

Before this, WPNV announced talks with Energy Plus, an Alternative Energy Company, regarding distribution of its Permanent Magnet Generator and Grid-Tie Technology throughout Mexico and Central America.

Energy Plus distributes alternative energy solutions throughout Mexico and Latin America, and the invitation to expand its palette of offerings, helping to address the requirements of its long standing relationships, represents a strategic marketing opportunity for WindPower Innovations and Energy Plus.

“Many potential markets for wind energy are un-tapped because the technology most widely available requires constant wind speeds at only one to two optimum peaks (+/-5%),” says Ian Griffiths, Chief Technical Officer of WindPower Innovations. “Since it’s a smart technology that can sense variable load demands and adjust power output accordingly, our Permanent Magnet and custom Grid-Tie solutions are ideal for regions that have inconsistent wind supply or power grid challenges, meeting the varying power needs from country to country, small villages, extreme climates and/or areas with developing infrastructure. Constant power can be generated consistently over a very wide band of operation (from 20% TO 125% of rated power).”

Shares of WPNV jumped up $0.07 (+100.00%), to $0.14 in today trading.

More about WPNV at: www.windpowerinnovationsinc.com

http://crwewallstreet.com/img/noc_logo.jpg

Northrop Grumman Corporation (NYSE:NOC) was presented with the Information Security Executive™ (ISE™) Southeast Project of the Year Award last month for the Northrop Grumman OneBadge program. Sponsored by Tech Exec Networks (TEN), the award recognizes projects for their outstanding achievements in risk management, data asset protection, compliance, privacy and network security.

The Northrop Grumman OneBadge program was selected as the winner in the project category that included nominees from the U.S. Southeast region including Alabama, Florida, Georgia, Kentucky, Maryland, Mississippi, North Carolina, South Carolina, Tennessee, Virginia and West Virginia.

TEN cited the project for, “successfully demonstrating a commercial enterprise’s ability to turn the merits of a federal directive into a successful internal deployment. Its far-reaching implications are paving the way for secure digital collaboration between government and industry at a time when cyber security is paramount to the protection of the U.S. economy, and to the security and well being of the U.S. and its citizens.”

More about NOC at: www.northropgrumman.com

Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

******************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB).

http://crwewallstreet.com/img/crwewallstreet_buscard.jpg

 
Share/Bookmark
 
 
 
crownequityholdings.com |  pennyotcstock.com |  crowntradingsystems.com |  crwenews.com |  crwenewswire.com |  crwefinance.com |  crown.dynastycouncil.org |  doubleinstocks.com |  crwedomains.com |  crwenews.net |  crownpartnersinc.com |  stock-ir.com |  drstockpick.com |  crwewallstreet.com |  crownbazar.com |  crownbeautymall.com |  dynastycouncil.info |  dynastycouncil.net |  dynastycouncil.org |  crwefinance.com |  stockhottips.com |  stock-pr.com |  pennyomega.com |  doctorstockpick.com |  bestotc.com |  crwepicks.com |  crweselect.com |  pennygovernance.com